Patents Assigned to Pharmacia & Upjohn Co.
-
Patent number: 7572924Abstract: The present invention relates to pyrrole substituted-2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: GrantFiled: September 6, 2006Date of Patent: August 11, 2009Assignees: Sugen, Inc., Pharmacia & Upjohn Co.Inventors: Peng Cho Tang, Todd Anthony Miller, Xiaoyuan Li, Connie Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
-
Publication number: 20090075316Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.Type: ApplicationFiled: July 18, 2008Publication date: March 19, 2009Applicant: PHARMACIA & UPJOHN CO.Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
-
Publication number: 20080171349Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.Type: ApplicationFiled: July 11, 2007Publication date: July 17, 2008Applicant: PHARMACIA & UPJOHN CO.Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
-
Patent number: 7144897Abstract: Disclosed are compounds of formula X, which are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising compounds of formula X and methods of preparing the compounds of formula X are also disclosed.Type: GrantFiled: May 31, 2002Date of Patent: December 5, 2006Assignees: Elan Oharmaceuticals, Inc., Pharmacia & Upjohn, Co.Inventors: John Freskos, David L. Brown, Yvette M. Fobian, Larry Fang, Arthur Glenn Romero, Varghese John
-
Patent number: 6951950Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.Type: GrantFiled: October 17, 2003Date of Patent: October 4, 2005Assignee: Pharmacia & Upjohn CoInventors: Ivan Michael Richards, Timothy Gordon Heath, Martin Durham Meglasson
-
Patent number: 6946486Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.Type: GrantFiled: October 17, 2003Date of Patent: September 20, 2005Assignee: Pharmacia & Upjohn Co.Inventor: John Gregory Slatter
-
Patent number: 6916914Abstract: This invention discloses a commercially advantageous process for extraction and purification of protein from microorganisms. The initial steps of the process are useful for purifying many insoluble proteins while later steps are designed to renature denatured somatotropins produced by transformed microorganisms. The process is especially useful for purifying recombinantly-produced bovine somatotropin.Type: GrantFiled: June 13, 1986Date of Patent: July 12, 2005Assignee: Pharmacia & Upjohn Co.Inventors: Timothy W. Evans, Mark W. Knuth
-
Publication number: 20040127542Abstract: The present invention is directed to 1-pyrrolidin-1-ylmethyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.Type: ApplicationFiled: May 5, 2003Publication date: July 1, 2004Applicant: Pharmacia & Upjohn Co.Inventors: Malcolm Wilson Moon, Walter Morozowich, Ping Gao
-
Publication number: 20040063773Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: ApplicationFiled: April 14, 2003Publication date: April 1, 2004Applicant: SUGEN, Inc. & Pharmacia & Upjohn Co.Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Thomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
-
Patent number: 6673793Abstract: The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.Type: GrantFiled: June 28, 2001Date of Patent: January 6, 2004Assignee: Pharmacia & Upjohn Co.Inventors: Steven Ronald Turner, Suvit Thaisrivongs, Atli Thorarensen
-
Patent number: 6624160Abstract: This invention provides compounds of formula I; which are useful as antiviral agents.Type: GrantFiled: March 15, 2001Date of Patent: September 23, 2003Assignee: Pharmacia & Upjohn Co.Inventors: Valerie A. Vaillancourt, Scott D. Larsen, Sajiv K. Nair
-
Patent number: 6573293Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.Type: GrantFiled: February 15, 2001Date of Patent: June 3, 2003Assignees: Sugen, Inc., Pharmacia & Upjohn Co.Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
-
Patent number: 6395708Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin- analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.Type: GrantFiled: August 25, 2000Date of Patent: May 28, 2002Assignees: Novartis, A.G., Pharmacia & Upjohn Co.Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd
-
Patent number: 6387896Abstract: The present invention provides compounds of formula I useful as antimicrobial agents wherein W, X, Y, R1, R2 and n are as defined in thereof.Type: GrantFiled: May 17, 2000Date of Patent: May 14, 2002Assignee: Pharmacia & Upjohn Co.Inventors: Michael J. Genin, Michael Robert Barbachyn, Jackson B. Hester, Jr., Paul D. Johnson
-
Patent number: 6387900Abstract: 3-ureido-pyrazole derivatives represented by formula (I): where R, R1 and R2 are as described herein, or pharmnaceutically acceptable salts thereof; are useful, for example, for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.Type: GrantFiled: August 12, 1999Date of Patent: May 14, 2002Assignees: Pharmacia & Upjohn S.p.A., Pharmacia & Upjohn Co.Inventors: Paolo Pevarello, Paolo Orsini, Gabriella Traquandi, Mario Varasi, Edward L. Fritzen, Martha A. Warpehoski, Betsy S. Pierce
-
Patent number: 6218418Abstract: Compounds which are 3-amino-pyrazole derivatives represented by formula (I): where R is a C3-C6 cycloalkyl group, which may optionally be substituted by a straight or branched C1-C6 alkyl group, and R1 is a straight or branched C1-C6 alkyl group or a C2-C4 alkenyl, cycloalkyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl and arylalkenyl, which may be optionally substituted; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.Type: GrantFiled: September 22, 2000Date of Patent: April 17, 2001Assignees: Pharmacia & Upjohn S.p.A, Pharmacia & Upjohn Co.Inventors: Paolo Pevarello, Paolo Orsini, Gabriella Traquandi, Mario Varasi, Edward L. Fritzen, Martha A. Warpehoski, Betsy S. Pierce, Maria Gabriella Brasca
-
Patent number: 6159935Abstract: The present invention relates to a method for preventing irinotecan-induced or camptothecin-induced or camptothecin-analog-induced diarrhea by administering an effective amount of octreotide. In particular the invention concerns new methods, combination formulations and kits to prevent late diarrhea caused by irinotecan or camptothecin, or camptothecin-analog administration.Type: GrantFiled: November 29, 1999Date of Patent: December 12, 2000Assignees: Pharmacia & UpJohn Co., Novartis, A.G.Inventors: Langdon L. Miller, John David Rothermel, Hugh Michael O'Dowd